New Radiotherapy Approach Offers Hope for Advanced Lung Cancer Patients

Doctors are hailing a significant advance in the treatment of advanced lung cancer, with new research indicating that adding radiotherapy to standard care can extend the time patients live without their disease worsening. The findings, presented at the European Society of Medical Oncology’s annual meeting in Madrid, suggest this approach can add an average of five months of progression-free life.

Advanced non-small cell lung cancer (NSCLC) is often considered incurable, with limited treatment options for patients whose cancer has already spread beyond the lungs. Typically, only about 15% of patients survive for five years.

The SARON trial, which involved 140 patients across 19 UK centers, investigated the benefits of incorporating localized radiotherapy into standard chemotherapy or immunotherapy regimens. Patients in the trial had advanced NSCLC that had spread to up to three organs.

Results showed that patients receiving radiotherapy directed at all known sites of disease, including the primary tumor, lymph nodes, and secondary tumors, lived for over a year without their cancer progressing. In contrast, those receiving standard treatment saw their disease worsen in an average of eight months. Furthermore, only 13% of patients treated with radiotherapy experienced tumor growth in the year following treatment, compared to nearly 40% of those on standard care.

Experts involved in the trial emphasized that the radiotherapy was well-tolerated and did not negatively impact patients' quality of life. Dr. Fiona McDonald, chief investigator of the trial and a consultant oncologist at The Royal Marsden, stated that the trial provided crucial data on the benefits of adding radiotherapy for patients with oligometastatic NSCLC, demonstrating significant improvement in progression-free survival. She highlighted the importance of such national collaborations in informing personalized treatment strategies.

Cancer Research UK welcomed the findings, noting that the treatment approach could provide patients with more valuable time. Dr. Dani Skirrow, the charity's science engagement manager, commented that being able to keep the disease stable is immensely important for maintaining a better quality of life, allowing individuals more time with loved ones.

One patient, Julie Moran, a 69-year-old former cardiac technician, shared her experience. Diagnosed with advanced lung cancer in 2020 after a persistent cough, she was enrolled in the trial. Six years later, her disease remains stable after receiving immunotherapy followed by radiotherapy. She has been able to return to work and now enjoys spending time with her grandchildren and great-grandchild, crediting the treatment for her prolonged stability.